After Trump’s Marijuana Executive Order, Will the DEA Face a Court Imposed Deadline from MMJ’s Writ of Mandamus?
Black Book Research Releases Its 2026 Annual Methodology and Governance Statement for Healthcare IT Vendor Rankings
Black Book Research Releases Its 2026 Annual Methodology and Governance Statement for Healthcare IT Vendor Rankings
Awake Breast Augmentation: Gruber Plastic Surgery Highlights Live Implant Sizing Under Local Anesthesia With No Sedation for Eligible Patients
Clemson University and Nordic Wellness Launch Groundbreaking Partnership to Transform the Student Mental Health Crisis
- Combination of evorpacept plus rituximab and lenalidomide (R2) generated complete responses (CR) in 92% of patients with untreated indolent...
Media ReleaseCOPENHAGEN, Denmark; December 7, 2025 Trial demonstrated treatment with fixed duration EPKINLY plus rituximab and lenalidomide (EPKINLY+ R2) resulted...
― Clear dose-response observed, with a robust and clinically meaningful fetal hemoglobin (HbF) induction at the Week 6 timepoint (n=12):...
Treatment arm continues to demonstrate favorable relapse-free survival (HR=0.50; p=0.23) and overall survival (HR=0.61; p=0.52) 3/3 (100%) of TSC-101-treated patients...
Selective Treg modulator gotistobart (BNT316/ONC-392) showed a reduction in the risk of death by more than half compared to standard...
KEY LARGO, Fla., Dec. 06, 2025 (GLOBE NEWSWIRE) -- Remedy's Nutrition®, a trusted natural supplement company since 1972 and a...
Triple-class exposed patients with three prior lines of therapy in CARTITUDE-1 and CARTITUDE-4 achieved a median PFS of 50.4 months...
Designed with our proprietary AI-Immunology™ platform based on patient sequencing data, EVX-04 targets multiple non-conventional endogenous retrovirus (ERV) tumor antigensEVX-04...
First disclosure of PRT12396, a JAK2V617F-selective JH2 inhibitor demonstrates disease modifying potential in myeloproliferative neoplasms PRT12396 has completed GLP toxicology...
Lisaftoclax monotherapy demonstrated significant and durable clinical efficacy and a manageable safety profile in patients with heavily pretreated BTK-refractory R/R...
Follow-up data from CARTITUDE-4 show at least 80 percent of as-treated standard-risk patients remained progression- and treatment-free following a single...
-- Bezuclastinib achieves clear clinical benefit across all symptom domains including significant improvements on 11 individual symptoms plus the most...
Objective response rate (ORR) of 83% including two complete responses in CLL patients in Phase 1a study with median progression...
Media ReleaseCOPENHAGEN, Denmark; December 6, 2025 New two- and three-year EPCORE® NHL-2 follow-up data evaluating epcoritamab in combination with standard...
VANCOUVER, BC / ACCESS Newswire / December 7, 2025 / Onco-Innovations Limited (CBOE CA:ONCO)(OTCQB:ONNVF)(Frankfurt:W1H, WKN: A3EKSZ) ("Onco" or the "Company")...
New multilingual capabilities expand access to real-time GLP-1 dining guidance as WHO highlights the importance of protein-focused nutrition.BOSTON, Dec. 6,...
ATLANTA, GA AND DOHA, QATAR / ACCESS Newswire / December 6, 2025 / Ameerex Corporation (OTC:HIRU) ("Ameerex" or the "Company"),...
SEATTLE, Dec. 06, 2025 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to...
– Data support initiation of a combination cohort in the ongoing Phase 1 clinical trial to evaluate ARV-393 plus glofitamab...
SPRING, Texas, Dec. 06, 2025 (GLOBE NEWSWIRE) -- Io Therapeutics, Inc., a privately held pharmaceutical company headquartered in Spring, Texas;...
